Job title: Head of Global Gene Therapy Research
Vivian has spent nearly two decades in gene therapy research at both academic and industrial drug development settings. Vivian joined Shire in 2015 as the Head of Gene Therapy Research, US, and integrated into Takeda after the acquisition in 2019. Vivian’s main roles include driving the Gene Therapy Research Strategy, leading and advising discovery gene therapy programs involved in multiple therapeutic areas utilizing gene transfer, gene regulation and gene editing, and establishing internal vectorology capabilities. She was previously an investigator and global project team lead at Novartis Institutes for BioMedical Research where she led multiple ophthalmic gene therapy projects, as well as establishing the platform for developing rAAV vector as a modality. She received her Ph.D. in Pharmacology from University of North Carolina at Chapel Hill studying recombinant AAV vector biology and its application in gene therapy and postdoctoral training in Genetics and Immunology at Harvard Medical School investigating natural and artificial nuclease-induced genomic DNA double strand breaks and the intra/inter chromosomal DNA repair mechanisms in gene editing in the immunoglobulin genes.
Panel Discussion: Contrasting Analytical Requirements for AAV and Lentiviral Vectors 1:45 pm
Discussing the relative advantages and disadvantages of lentiviral and AAV vector approaches in a variety of indications Understanding how analytical strategies differ in the context of different viral vectors Case studies detailing similarities and differences in the analytical approaches required for the analysis of different vectorsRead more
day: Day Two
Contrasting qPCR and ddPCR Methods for Vector Titering 11:00 am
What’s the best method to use? Investigating the advantages and disadvantages of qPCR and ddPCR at various stages of development How to use titer methods to support the process as well as releasing the drug Understanding how to successfully transition from early stage qPCR to ddPCR for commercial material: how to address differences through comparability…Read more
day: Day Two